As part of the Ministry of Health's efforts to boost the immunity of population groups that are most vulnerable to serious disease, the National Advisory Committee on Vaccination, at today's meeting, recommends the following:
1st Recommendation:
The administration of a booster/3rd dose of vaccine, to persons 12 years of age and older with MRNA technology vaccines meaning that the six (6) month period has elapsed since receiving the 2nd dose. It is understood that the validity of the European Digital Certificate (SafePass) is not affected in case of non-receipt of a booster dose.
2nd Recommendation:
The administration of a booster/4th dose of vaccine:
1. To persons over 70 years of age, provided that a period of five (5) months has elapsed
2. In persons of any age, provided that a period of five (5) months has elapsed since receiving the booster/3rd dose:
- Residents and workers in nursing homes and other closed institutions,
- Health care professionals,
- Immunosuppressed persons (see list below).
- In active treatment for solid tumours and haematological malignancies
- With a history of solid organ transplantation receiving immunosuppressive therapy
- With a history of primary hematopoietic organ transplantation receiving immunosuppressive therapy
- Individuals with hereditary immunodeficiency
- Persons with HIVInfection/AIDS
- Persons on immunosuppressive therapy including biological agents
- With regard to receiving cortisone refers to individuals who have received or are receiving a total dose of '10mg of prednisone/day (=8mg of methylprednisolone) for one (1) month in the last six months.
- With renal failure undergoing dialysis or peritoneal dialysis.
Please note that the validity of the European Digital Certificate (SafePass) is not affected if the booster/4th dose is not taken.
The recommendations of the National Advisory Committee on Vaccination of the Ministry of Health will be endorsed by the Council of Ministers at a subsequent meeting.
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO
Source
